Affiliation:
1. Department of Pharmaceutical Sciences, “Department of Excellence 2018–2022”, University of Perugia, 06123 Perugia, Italy
Abstract
AKT (also known as PKB) is a serine/threonine kinase that plays a pivotal regulatory role in the PI3K/AKT/mTOR signaling pathway. Dysregulation of AKT activity, especially its hyperactivation, is closely associated with the development of various human cancers and resistance to chemotherapy. Over the years, a wide array of AKT inhibitors has been discovered through experimental and computational approaches. In this regard, herein we present a comprehensive overview of AKT inhibitors identified using computer-assisted drug design methodologies (including docking-based and pharmacophore-based virtual screening, machine learning, and quantitative structure–activity relationships) and successfully validated small molecules endowed with anticancer activity. Thus, this review provides valuable insights to support scientists focused on AKT inhibition for cancer treatment and suggests untapped directions for future computer-aided drug discovery efforts.
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Reference96 articles.
1. Defining the Akt1 interactome and its role in regulating the cell cycle;Duggal;Sci. Rep.,2018
2. AKT/PKB Signaling: Navigating the Network;Manning;Cell,2017
3. Targeting PI3K/Akt signal transduction for cancer therapy;He;Signal Transduct. Target. Ther.,2021
4. AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?;Martorana;Front. Pharmacol.,2021
5. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region;Bellacosa;Science,1991